Physician profile
Mark E Heinsohn
NPI 1457338014
$9,512.25
in general payments reported to CMS, 2019-2025
47 companies · $1,194 in 2025
The $1,194 reported for 2025 was more than what 87% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,711 · 2020: $1,065 · 2021: $1,734 · 2022: $1,510 · 2023: $1,171 · 2024: $1,127 · 2025: $1,194.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,419 · Education: $73.44.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,418.83 |
| Education | $73.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,157.69 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Amgen INC. | $1,153.35 | 2019-2025 | Repatha, Otezla, Evenity |
| Abbvie INC. | $912.93 | 2021-2025 | |
| Pfizer INC. | $883.45 | 2019-2025 | |
| Glaxosmithkline, LLC. | $660.87 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Novartis Pharmaceuticals Corporation | $569.28 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $516.81 | 2019-2022 | |
| Astellas Pharma US INC | $387.24 | 2019-2023 | Myrbetriq |
| Abbott Laboratories | $357.51 | 2022-2025 | Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals LP | $336.56 | 2019-2025 | Airsupra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $257.65 | 2019-2025 | Xifaxan, Trulance |
| Bayer Healthcare Pharmaceuticals INC. | $252.09 | 2021-2025 | |
| Lilly USA, LLC | $191.30 | 2021-2025 | Mounjaro |
| Otsuka America Pharmaceutical, INC. | $168.65 | 2023-2025 | Rexulti |
| Biohaven Pharmaceuticals, INC. | $165.81 | 2020-2021 |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Heinsohn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.